Retrophin, Inc. (NASDAQ:RTRX) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.10, Bloomberg Earnings reports. The firm had revenue of $38.80 million for the quarter, compared to the consensus estimate of $37.36 million. Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.25%. The firm’s revenue for the quarter was up 16.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.07 earnings per share.

Shares of Retrophin (NASDAQ:RTRX) traded up 5.66% during mid-day trading on Friday, hitting $21.83. 373,941 shares of the stock were exchanged. The stock’s market cap is $835.87 million. The stock’s 50 day moving average is $19.83 and its 200-day moving average is $19.02. Retrophin has a 12 month low of $15.55 and a 12 month high of $24.57.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/retrophin-inc-nasdaqrtrx-announces-earnings-results/1475900.html.

A number of brokerages have recently issued reports on RTRX. ValuEngine downgraded shares of Retrophin from a “hold” rating to a “sell” rating in a report on Friday, July 28th. TheStreet raised shares of Retrophin from a “d” rating to a “c-” rating in a report on Friday, May 12th. Finally, Zacks Investment Research downgraded shares of Retrophin from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 3rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Retrophin currently has an average rating of “Buy” and an average price target of $32.25.

Large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. bought a new stake in Retrophin during the fourth quarter valued at approximately $387,000. Dimensional Fund Advisors LP raised its position in shares of Retrophin by 26.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 360,270 shares of the biopharmaceutical company’s stock worth $6,820,000 after buying an additional 75,221 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Retrophin during the fourth quarter worth about $782,000. Teachers Advisors LLC raised its position in shares of Retrophin by 5.9% in the fourth quarter. Teachers Advisors LLC now owns 293,088 shares of the biopharmaceutical company’s stock worth $5,548,000 after buying an additional 16,214 shares during the period. Finally, Highbridge Capital Management LLC acquired a new position in shares of Retrophin during the fourth quarter worth about $243,000.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Earnings History for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.